Browse the University's technologies that are available for licensing, and keep up to date with technologies that have been recently licensed.
Tissue-engineered corneal endothelium graft
Researchers at the University of Melbourne have developed tissue-engineered corneal endothelium (TECE) grafts for the treatment of corneal dysfunction.
Researchers have identified the CCL17 cytokine as a target for monoclonal antibody inhibition of the GM-CSF-driven pain pathway. It has the potential to improve pain treatments for chronic conditions.
Severe asthma therapy
This is a treatment for severe, steroid-resistant asthma. It enhances steroid activity by selectively inhibiting signaling pathways downstream of TGFẞ.